Anrukinzumab
Modify Date: 2024-04-09 16:10:41
Anrukinzumab structure
|
Common Name | Anrukinzumab | ||
|---|---|---|---|---|
| CAS Number | 910649-32-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AnrukinzumabAnrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3]. |
| Name | Anrukinzumab |
|---|
| Description | Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IL-13[1][2][3]. |
| In Vivo | Anrukinzumab (IMA-638; 10 mg/kg; intravenous infusion; single) 减少食蟹猕猴肺部炎症模型中的肺部炎症[1]。 Animal Model: Adult male cynomolgus monkeys (6 to 10 kg; cynomolgus monkey model of lung inflammation)[1]. Dosage: 10 mg/kg Administration: Intravenous infusion; single Result: Reduced total BAL cell count, eosinophil number, and neutrophil number. Reduced the levels of eotaxin and RANTES in BAL fluid. |
| References |
| No Any Chemical & Physical Properties |